Tuesday, February 9, 2010
  • Font size
  • Bookmark
  • Save

Clinical trial: Vaccine study for melanoma

(National Institutes of Health) UPDATED 2009-07-16
This is a study to determine whether M-Vax is effective in shrinking melanomas that have spread (stage IV). To increase it effectiveness, the M-Vax dosing will be followed by administration of low doses of interleukin-2 (IL2), a marketed drug that is known to stimulate immunity and cause some shrinkage of melanomas. This national study is currently recruiting patients who have Stage IV melanoma and who meet the study's other criteria.
  Read full story >
See all Skin Cancer News
  • Font size
  • Bookmark
  • Was this helpful? Yes
  • Save

People who read this also read...